Weight-loss drugs that mimic the hormone GLP-1 appear to do more than trim waistlines. A retrospective study presented on Monday at the Endocrine Society’s annual meeting in San Francisco found that semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Zepbound) helped restore testosterone to normal ranges in men with obesity or Type 2 diabetes. Researchers at SSM Health St. Louis University Hospital reviewed electronic health records for 110 men treated with the injectables and not receiving testosterone therapy. Eighteen months after starting the medication, participants had lost an average of 10 % of their body weight, and the proportion with normal testosterone levels rose to 77 % from 53 %. The authors said the improvement likely reflects recovery of the body’s own hormone production as fat mass and insulin resistance declined. Clinicians who prescribe GLP-1 drugs to men already on testosterone supplements may need to reassess dosage, the investigators noted. While the hormonal lift was less dramatic than that seen after bariatric surgery, it occurred without invasive procedures and added to the drugs’ metabolic benefits. The team called for prospective trials to confirm the link and to track hormone levels after therapy is stopped. In a separate presentation at the same meeting, researchers reported that combining menopause hormone therapy with tirzepatide produced greater weight loss in post-menopausal women than the drug alone, underscoring the broader endocrine effects being explored for the fast-growing class of obesity medicines.